MediPoint: Enteral Stents - Europe Forecast and Market Analysis
European market for enteral stents, which encompasses 21 countries and includes esophageal stents, gastrointestinal stents, and colonic stents, was valued at approximately $49M in 2016. The market is expected to grow at a CAGR of 3.4%, to reach a valuation of $61.8M in 2023.
Enteral stents are a palliative treatment option for constrictions caused primarily by various cancers. The primary cancers which cause constrictions requiring the use of enteral stents are esophageal cancer, gastric cancer, pancreatic cancer, and colorectal cancer. There are three primary enteral stents; the covered enteral stent, the partially covered enteral stents, and the non-covered enteral stent.
Enteral stents market is a leading non-vascular stents market. This market includes esophageal stents, gastroduodenal stents, and colonic stents, and is divided into three segments: fully covered enteral stents, partially covered enteral stents, and non-covered enteral stents. As a whole, the enteral stents market is increasing, primarily due to globally rising cancer rates.
Globally, fully covered stents retain the largest market share. They tend to be preferred over partially covered and non-covered enteral stents, especially in the case of esophageal stents, as they have the lowest risk of tumor or tissue ingrowth. The non-covered enteral stents market, however, is a declining market, as they are more likely to result in tumor ingrowth and result in further complications. This trend is seen throughout the global enteral stents market.0
The key drivers of this market during the forecast period are -
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook